PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19622833-3	2009	We show that administration of l-DOPA in a mouse model of Parkinsonism led to dopamine D1 receptor-mediated activation of the mammalian target of rapamycin (mTOR) complex 1 (mTORC1), which is implicated in several forms of synaptic plasticity.	Levodopa	31-37	mechanistic target of rapamycin kinase	Homo sapiens	126-155	
19622830-1	2009	In a mouse model of Parkinson"s disease, new evidence shows that l-DOPA, which is used to treat the symptoms of the disease but also causes dyskinesia, results in a persistent activation of the protein kinase mTOR (mammalian target of rapamycin) in a subset of striatal medium spiny neurons.	Levodopa	65-71	mechanistic target of rapamycin kinase	Homo sapiens	215-244	
22179112-1	2011	L-DOPA-induced dyskinesia, the rate-limiting side effect in the therapy of Parkinson"s disease, is mediated by activation of mammalian target of rapamycin (mTOR) signaling in the striatum.	Levodopa	0-6	mechanistic target of rapamycin kinase	Homo sapiens	125-154	
22179112-1	2011	L-DOPA-induced dyskinesia, the rate-limiting side effect in the therapy of Parkinson"s disease, is mediated by activation of mammalian target of rapamycin (mTOR) signaling in the striatum.	Levodopa	0-6	mechanistic target of rapamycin kinase	Homo sapiens	156-160	
19622833-3	2009	We show that administration of l-DOPA in a mouse model of Parkinsonism led to dopamine D1 receptor-mediated activation of the mammalian target of rapamycin (mTOR) complex 1 (mTORC1), which is implicated in several forms of synaptic plasticity.	Levodopa	31-37	mechanistic target of rapamycin kinase	Homo sapiens	157-161	
29992529-0	2019	MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson"s Disease Patients.	Levodopa	58-64	mechanistic target of rapamycin kinase	Homo sapiens	0-4	
29992529-4	2019	We screened 64 single nucleotide polymorphisms (SNPs) mapping to 57 genes of the mTOR pathway in a retrospective cohort of 401 PD cases treated with L-DOPA (70 PD with moderate/severe LID and 331 with no/mild LID).	Levodopa	149-155	mechanistic target of rapamycin kinase	Homo sapiens	81-85	
24144882-4	2013	Furthermore, this pathway is also dysfunctional and pathogenically linked to mTOR signaling in L-DOPA-induced dyskinesias (LID).	Levodopa	95-101	mechanistic target of rapamycin kinase	Homo sapiens	77-81	
32426479-6	2020	Besides acting as a GEF for Ras homolog enriched in the brain (Rheb), the activator of the mammalian target of rapamycin kinase (mTOR), RasGRP1 promotes l-DOPA-induced extracellular signal-regulated kinase (ERK) and the mTOR signaling in the striatum.	Levodopa	153-159	mechanistic target of rapamycin kinase	Homo sapiens	91-127	
32426479-6	2020	Besides acting as a GEF for Ras homolog enriched in the brain (Rheb), the activator of the mammalian target of rapamycin kinase (mTOR), RasGRP1 promotes l-DOPA-induced extracellular signal-regulated kinase (ERK) and the mTOR signaling in the striatum.	Levodopa	153-159	mechanistic target of rapamycin kinase	Homo sapiens	129-133	
32426479-6	2020	Besides acting as a GEF for Ras homolog enriched in the brain (Rheb), the activator of the mammalian target of rapamycin kinase (mTOR), RasGRP1 promotes l-DOPA-induced extracellular signal-regulated kinase (ERK) and the mTOR signaling in the striatum.	Levodopa	153-159	mechanistic target of rapamycin kinase	Homo sapiens	220-224	
32146463-3	2019	RESULTS: In this work, our results showed clear modifications in the expression of kinases involved in mTOR and PKR apoptosis pathways, in lymphocytes of PD patients treated or not with anti-PD treatment (levodopa), which confirmed the role played by apoptosis in the pathogenesis of this disease and the positive effect of treatment with medication on this parameter.	Levodopa	205-213	mechanistic target of rapamycin kinase	Homo sapiens	103-107